Several cancer and adjunctive therapies (including anti-emetics, opioids, and antibiotics) can alter CYP3A4 metabolism [113] and, therefore, careful consideration is encouraged before administering these therapies together with DOACs. The gene discussed is CYP3A4; the disease is cancer.